Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Metrics to compare | OBD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOBDPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.8x | −2.6x | −0.5x | |
PEG Ratio | −0.02 | −0.02 | 0.00 | |
Price/Book | 2.0x | 2.6x | 2.6x | |
Price / LTM Sales | 13.9x | 4.1x | 2.9x | |
Upside (Analyst Target) | - | 80.7% | 58.9% | |
Fair Value Upside | Unlock | 9.3% | 8.0% | Unlock |